Thank you for your inquiry.
We will contact you within a few business days.
(Business Unit Performance Materials, Sales Support Team)
Gedung AIA Central, Level 39, Jl. Jend. Sudirman Kav. 48A, Jakarta Selatan, Indonesia
+62 21 2988 8557
Success! Your inquiry has been submitted to our Sales team.
Something went wrong! Please try after some time.
We have found 22 items.
| Requestor's contact details | |
| Full name | |
| Company | |
| Position | |
| Telephone number | |
| Work email address | |
| Shipping address | |
Thank you. Your request has been sent.
Bilastine is a white to off-white crystalline powder that is sparingly soluble in methylene chloride and practically insoluble in acetone. It has an assay range of 98.0% to 102.0%.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Atorvastatin Calcium, provided by Refarmed Chemicals, is a potent pharmaceutical ingredient used by healthcare professionals in the management and prevention of several cardiovascular-related conditions. As an integral part of the statin class of medications, Atorvastatin Calcium serves a critical role in reducing cholesterol levels, specifically low-density lipoprotein (LDL) cholesterol, apolipoprotein B, and total cholesterol. It is also effective in lowering triglyceride levels and is indicated for the prevention of cardiovascular events such as ischemic strokes and transient ischemic attacks, particularly in patients who are at high risk of these events. This product is especially valuable for the treatment of familial heterozygous and homozygous hypercholesterolemia. However, it is contraindicated in individuals with known hypersensitivity to the active ingredient, those suffering from active liver disease, and should not be used during pregnancy and breastfeeding due to potential risks. Formulated as a white or almost white yellowish crystalline powder, Atorvastatin Calcium comes with comprehensive documentation and certifications, such as the Certificate of Suitability (CEP) and Good Manufacturing Practice (GMP) standards, ensuring its quality and safety. The material's purity is rigorously controlled, with an assay requirement of 98.0% to 102.0%, minimal water content, and strict limits on enantiomer impurities as well as residual solvents such as Methanol and Methyl tert-butyl ether, as specified in the provided image of its typical properties. Patients prescribed Atorvastatin Calcium should be under close medical supervision to monitor liver function and signs of muscle damage, a potential adverse effect. Muscle pain, diarrhea, nausea, headache, and flatulence are among the commonly reported side effects. Moreover, Atorvastatin Calcium can interact with several other medications, necessitating careful review by healthcare professionals when determining a patient's regimen. Refarmed Chemicals' rigorous adherence to quality and patient safety, as exemplified by their Atorvastatin Calcium product, fulfills the expectation of effectiveness and reliability desired by healthcare providers and wholesalers looking to distribute a product that can make a significant impact on public health.
Products still subject to third-party patent protection might be available solely for R&D purposes.
**Product Overview: Febuxostat – A Robust Solution for Gout Management** Refarmed Chemicals presents Febuxostat, a meticulously prepared medication aimed at alleviating the pain and discomfort associated with gout. Made from a refined white powder, Febuxostat stands out in the pharmaceutical industry as a Xanthine Oxidase Inhibitor, crucial for managing hyperuricemia and recurrent gout attacks. Structured to meet corporate expectations, Febuxostat is a testament to Refarmed Chemicals' 30-year expertise in delivering quality generic and branded medications. Manufactured in compliance with strict guidelines, including the Drug Master File (DMF) and certifications such as WC and GMP, this product is a model of reliability and efficacy. Febuxostat's fundamental use is to decrease blood uric acid levels, offering those afflicted with gout a pathway to recovery by preventing acute flare-ups, and mitigating inflammation and pain in the joints. As a white, soluble powder, Febuxostat is highly soluble in DMSO and slightly soluble in methanol and water, simplifying its integration into diverse medical formulations. Clinical trials have informed a standard starting dosage of 40 mg, adjustable up to 80 mg based on individual patient requirements and the severity of symptoms. In its commitment to patient welfare, Refarmed Chemicals underlines potential side effects ranging from nausea and headaches to rashes, ensuring informed usage of Febuxostat. In alignment with our promise of transparency and safety, we advise consulting healthcare professionals for precise diagnotics and treatment plans. Furthermore, users should be attentive to contraindications, noting that Febuxostat is unsuitable for patients with severe liver or kidney disease, or for women who are pregnant or breastfeeding. Refarmed Chemicals' Febuxostat exceeds industry standards with its impressive assay value of 98.0% - 102.0% purity and a precise control of impurities, ensuring that the product meets stringent quality criteria. The company's analytical rigor is reflected in the detailed specification of residual solvents such as Acetone, Ethanol, and Isopropanol. In the journey to deliver improved health outcomes, Refarmed Chemicals' Febuxostat is more than just a medication; it symbolizes our dedication to quality, safety, and corporate responsibility in the global pharmaceutical landscape. [*Note: Product image depicts a detailed specification chart for Febuxostat, reiterating its quality and compositions.*]
Products still subject to third-party patent protection might be available solely for R&D purposes.
Deferasirox, marketed under the brand Refarmed Chemicals, is a cornerstone in the treatment of chronic iron overload due to blood transfusions in conditions such as thalassemia and sickle cell disease. This condition, if not properly managed, can have severe consequences for organ function. Deferasirox is available in oral tablet form, with strengths of 250 mg, 500 mg, and 1000 mg, allowing for flexibility and precision in dosing to meet individual patient needs. Crafted as an iron chelator, Deferasirox plays a crucial role in binding excess iron within the body and facilitating its excretion through urine. This targeted mechanism asserts its importance in maintaining a healthy balance of iron and preventing the potential toxicity associated with overload. Patients are advised to take Deferasirox with or without food, adhering to a dosing schedule that is tailored to their specific iron levels and bodily response, underscoring the need for a personalized approach to treatment. Regarding its physical properties, Deferasirox appears as a white to pale yellowish crystalline powder, primarily soluble in DMF (Dimethylformamide) and slightly soluble in methanol. These characteristics are essential for ensuring its effectiveness and stability as a pharmaceutical agent. It is imperative that patients undergo regular blood tests and health monitoring for optimum results and to prevent adverse effects such as gastrointestinal distress, skin reactions, and potential liver or renal impairment. Additionally, care must be taken in cases of known hypersensitivity to Deferasirox or pre-existing severe renal or liver conditions. Our documentation and certifications like Good Manufacturing Practice (GMP) and the Drug Master File (DMF) guarantee the highest levels of quality and compliance with industry standards. It is our priority to ensure that this crucial pharmaceutical material is of the utmost purity and efficacy, as reflected in our stringent quality control parameters including the presence of residual solvents and related substances, all documented for your assurance. Please note that while Deferasirox is a vital medication for many patients, it requires diligent medical supervision. Always consult healthcare professionals for specific medical advice and treatment instructions tailored to individual health profiles.
Products still subject to third-party patent protection might be available solely for R&D purposes.